[1] |
何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4): 313-325.
|
[2] |
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10): 1938-1956.
|
[3] |
Miranda-Silva W, Montezuma MA, Benites BM, et al. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals[J]. Support Care Cancer, 2020, 28(11): 5397-5404.
|
[4] |
Ruggiero SL, Dodson TB, Aghaloo T, et al. American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws—2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5): 920-940.
|
[5] |
孙国文, 田美. 药物相关性颌骨坏死不同阶段治疗方法述评[J]. 口腔颌面外科杂志, 2022, 32(3): 135-143.
doi: 10.3969/j.issn.1005-4979.2022.03.001
|
[6] |
Khan AA, Morrison A, Hanley DA, et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus[J]. J Bone Miner Res, 2015, 30(1): 3-23.
doi: 10.1002/jbmr.2405
pmid: 25414052
|
[7] |
Topaloglu G, Koseoglu OT, Karaca C, et al. The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw[J]. J Cranio Maxillofac Surg, 2017, 45(8): 1158-1164.
|
[8] |
Sharma S, Shankar R, Ravi Kiran BS, et al. A narrative review of osteonecrosis of the jaw: What a clinician should know[J]. Cureus, 2023, 15(12): e5118.
|
[9] |
Baba A, Ojiri H, Goto TK, et al. Symposium: Imaging modalities for drug-related osteonecrosis of the jaw (4), CT and MR imaging findings of antiresorptive agent-related osteonecrosis of the jaws/medication-related osteonecrosis of the jaw (secondary publication)[J]. Jpn Dent Sci Rev, 2019, 55(1): 58-64.
|
[10] |
Wongratwanich P, Shimabukuro K, Konishi M, et al. Do various imaging modalities provide potential early detection and diagnosis of medication-related osteonecrosis of the jaw? A review[J]. Dentomaxillofacial Radiol, 2021, 50(6): 20200417.
|
[11] |
Moreno-Rabié C, Gaêta-Araujo H, Oliveira-Santos C, et al. Early imaging signs of the use of antiresorptive medication and MRONJ: A systematic review[J]. Clin Oral Investig, 2020, 24(9): 2973-2989.
|
[12] |
Olutayo J, Agbaje JO, Jacobs R, et al. Bisphosphonate-related osteonecrosis of the jaw bone: Radiological pattern and the potential role of CBCT in early diagnosis[J]. J Oral Maxillofac Res, 2010, 1(2): e3.
|
[13] |
Aghaloo TL, Dry SM, Mallya S, et al. Stage 0 osteonecrosis of the jaw in a patient on denosumab[J]. J Oral Maxillofac Surg, 2014, 72(4): 702-716.
|
[14] |
Shimamoto H, Grogan TR, Tsujimoto T, et al. Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws?[J]. Dentomaxillofac Radiol, 2018, 47(3): 20170290.
|
[15] |
Ozcan G, Sekerci AE, Gönen ZB. Are there any differences in mandibular morphology of patients with bisphosphonate-related osteonecrosis of jaws?: A case-control study[J]. Dentomaxillofac Radiol, 2016, 45(6): 20160047l.
|
[16] |
Soundia A, Hadaya D, Mallya SM, et al. Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018, 126(6): 537-544.
|
[17] |
Thomas C, Spanidis M, Engel C, et al. Bone scintigraphy predicts bisphosphonate-induced osteonecrosis of the jaw (BRONJ) in patients with metastatic castration-resistant prostate cancer (mCRPC)[J]. Clin Oral Investig, 2016, 20(4): 753-758.
|
[18] |
Yarom N, Shapiro CL, Peterson DE, et al. Medication-related osteonecrosis of the jaw: MASCC/ISOO/ASCO clinical practice guideline[J]. J Clin Oncol, 2019, 37(25): 2270-2290.
doi: 10.1200/JCO.19.01186
pmid: 31329513
|
[19] |
Liu C, Xiong YT, Zhu T, et al. Management of tooth extraction in patients taking antiresorptive drugs: An evidence mapping review and meta-analysis[J]. J Clin Med, 2022, 12(1): 239.
|
[20] |
潘剑, 刘济远. 药物相关性颌骨坏死的发病机制及其防治[J]. 华西口腔医学杂志, 2021, 39(3): 245-254.
|
[21] |
Takeda D, Kurita H, Kashima Y, et al. Is withdrawal of antiresorptive agents necessary before and after tooth extraction? A systematic review[J]. Clin Oral Investig, 2023, 28(1): 38.
|
[22] |
Ristow O, Rückschloß T, Moratin J, et al. Wound closure and alveoplasty after preventive tooth extractions in patients with antiresorptive intake-a randomized pilot trial[J]. Oral Dis, 2021, 27(3): 532-546.
|
[23] |
Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment[J]. Clin Oral Implants Res, 2014, 25(5): 632-640.
|
[24] |
陈珩, 何悦. MASCC/ISOO/ASCO药物相关性颌骨坏死临床实践指南解读[J]. 中华口腔医学杂志, 2022, 57(2): 128-135.
|
[25] |
蔡晨晨, 刘济远, 唐休发, 等. 药物相关性颌骨坏死治疗的研究进展[J/OL]. 中国医学前沿杂志(电子版), 2023, 15(5): 37-45.
|
[26] |
Soares AL, Simon S, Gebrim LH, et al. Prevalence and risk factors of medication-related osteonecrosis of the jaw in osteoporotic and breast cancer patients: A cross-sectional study[J]. Support Care Cancer, 2020, 28(5): 2265-2271.
doi: 10.1007/s00520-019-05044-0
pmid: 31468192
|
[27] |
Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: Definition and best practice for prevention, diagnosis, and treatment[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2019, 127(2): 117-135.
|
[28] |
Otto S, Tröltzsch M, Jambrovic V, et al. Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?[J]. J Craniomaxillofac Surg, 2015, 43(6): 847-854.
doi: 10.1016/j.jcms.2015.03.039
pmid: 25958767
|
[29] |
Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents[J]. Oral Dis, 2020, 26(5): 955-966.
doi: 10.1111/odi.13294
pmid: 32011077
|
[30] |
Varoni EM, Lombardi N, Villa G, et al. Conservative management of medication-related osteonecrosis of the jaws (MRONJ): A retrospective cohort study[J]. Antibiotics, 2021, 10(2): 195.
|
[31] |
Ottesen C, Schiodt M, Jensen SS, et al. Tooth extractions in patients with cancer receiving high-dose antiresorptive medication: A randomized clinical feasibility trial of drug holiday versus drug continuation[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2022, 133(2): 165-173.
|
[32] |
Campisi G, Mauceri R, Bertoldo F, et al. Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020[J]. Int J Environ Res Public Health, 2020, 17(16): 5998.
|
[33] |
Asaka T, Ohga N, Yamazaki Y, et al. Platelet-rich fibrin may reduce the risk of delayed recovery in tooth-extracted patients undergoing oral bisphosphonate therapy: A trial study[J]. Clin Oral Investig, 2017, 21(7): 2165-2172.
|
[34] |
郭玉兴, 王佃灿, 刘筱菁, 等. 翻瓣联合骨管技术拔牙方案在药物相关性颌骨坏死潜在风险患者中的应用初探[J]. 中华口腔医学杂志, 2021, 56(5): 452-457.
|
[35] |
Li JTW, Leung YY. Effect of antiresorptive drugs on osseointegrated dental implants: A systematic review[J]. J Clin Med, 2024, 13(7): 2091.
|
[36] |
Di Fede O, Panzarella V, Mauceri R, et al. The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention[J]. Biomed Res Int, 2018, 2018: 2684924.
|
[37] |
Hjortholt CO, Andersen SM, Jensen SS, et al. Dental implant treatment in patients with cancer on high-dose antiresorptive medication: A prospective feasibility study with 2 years follow-up[J]. Clin Oral Implants Res, 2024, 35(1): 63-76.
|
[38] |
Ciardo A, Simon MM, Awounvo S, et al. Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care[J]. Clin Oral Investig, 2023, 27(11): 6523-6536.
|